ClinicalTrials.gg
RecruitingNCT05023369Updated Sep 9, 2026

This is a Study to Verify if Periarticular Hip Injection of Corticosteroid After Hip Replacement Reduce the Pain and the Hospitalisation Time

A Phase 4 interventional study of Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml) in Femoral Neck Fractures, sponsored by Ente Ospedaliero Cantonale, Bellinzona. Recruiting at 1 site in Switzerland. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Ente Ospedaliero Cantonale, Bellinzona · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Study summary

The investigators are going to evaluate if periarticular corticosteroid injection during endoprothesis implantation can lead to any advantage to the patients, namely if it can reduce post-operative pain, lenght and cost of hospitalisation, use of analgesics drugs.

Read the detailed description

Hip endoprothesis is a common orthopaedic prosthetic procedure, with continuously growing numbers in the last years, and the demand for this procedure is predicted to increase 4-fold by 2030. Recently, major interest has been given to improve postoperative pain management, to decrease the discomfort of the patients and with an outlook for reducing the length of hospital stay and decrease health-care costs. However, postoperative pain management is still problematic after this operation.

Post-operative pain control with the optimization of the analgesia protocol is a key aspect to be addressed to reduce the need for opioid analgesics, to quicken recovery and mobilisation, and to decrease the hospitalization length. To this regard, steroid supplementation is considered effective in decreasing post-operative pain. A recent meta-analysis from our research group on patients with total knee prosthesis proved the efficacy in decreasing post-operative pain. Moreover, a positive effect has been documented in terms of lower incidence of nausea and vomit, less post-operative range of motion limitation, and decreased systemic inflammatory response. All these benefits produced a shortened length of hospital stay without an increased risk of complications such as local infections.

Despite this overall positive effect of steroid supplementation, and their use by other specialties - e.g. anaesthesiology - and while there is now good evidence about the benefits of periarticular hip analgesic injection, e.g. FANS, opioid etc., there is still lacking evidence on the efficacy of periarticular corticosteroids in patients undergoing hip prosthetic replacement. In fact, there is a lack of information in the literature on their effectiveness in terms of pain management and function recovery. Furthermore, the influence of perioperative steroid application on the long-term follow-up results is poorly explored. This is a key issue, since the intensity of acute post-operative pain has been widely related to the risk of developing chronic post-operative pain, and thus the advantages of steroid supplementation, could go beyond the short-term pain relief and be even longer lasting.

This randomized controlled trial will thus investigate the benefit of implementing the peri-operative analgesia protocol not only to improve the acute post-operative recovery and shorten the hospital stay, but also to optimize the overall results after hip endoprosthesis.

02

Conditions studied

  • Femoral Neck Fractures
03

In context

Femoral Neck Fractures

207 studies on the registry are indexed under Femoral Neck Fractures; 40 are open to participants now.

This study's planned enrollment of 110 is close to the median of 100 across 142 interventional studies indexed under Femoral Neck Fractures.

Browse Femoral Neck Fractures studies →

Lead sponsor

Ente Ospedaliero Cantonale, Bellinzona is the lead sponsor of 38 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing unilateral cemented hip endoprosthesis for femoral neck fracture
  • Patients aged 50-90 years old
  • Patients with a >18.5 and \<35
  • Patients able to provide and follow all the study procedures as indicated by the protocol
  • Informed Consent as documented by signature

Exclusion criteria

Exclusion Criteria:

  • to
  • Revision endoprosthesis
  • Active steroid or therapy in the last 30 days before the operation
  • Pregnant or breast-feeding women
  • Presence of other concomitant disease states ()
  • Uncontrolled diabetes mellitus
  • Contraindications to NSAIDs
  • Chronic systemic diseases as immunodeficiency, disease (Systemic Lupus Erythematosus, SLE), gout, rheumatic arthritis
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
  • Participation in another study with drug within the 30 days preceding and during the present study
  • Previous enrolment into the current study
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Dexamethasone group

    Patient in this group will receive administration of 9 mg dexamethasone injected in the peri-articular tissues after the bone cut for hip endoprosthesis

    Drug: Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)

  • No intervention
    Routine care

    In this group only routinely performed anaesthesia protocol will be provided

Interventions

  • DrugDexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)

    Dexamethasone will be administered as an injectable solution (4mg/ml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)

    Also known as: Mephameson

06

What researchers measure

Primary outcomes

  1. Postoperative pain

    The mean post-operative daily pain in the first three days after surgery assessed with the 0-10 numeric rating scale (NRS)

    Time frame: 3 days after surgery

Secondary outcomes

  1. Hip pain and function on a numeric rating scale (NRS)

    Hip pain and general function documented on a 0-10 NRS preoperatively and during the first 3 months, and reported on a 0-10 NRS at 2 and 6 weeks, 3, 6, 12, 24 months

    Time frame: Up to 24 months

  2. Hip pain, function and quality of life on Harris Hip Score

    hip pain, function and quality of life evaluated by the validated clinical Harris Hip Score preoperatively and at 2 and 6 weeks, and at 3, 6, 12, 24 months postoperatively. The Harris Hip Score is a measure of dysfunction; the maximum score possible is 100 and the higher the score, the better the outcome for the individual.

    Time frame: Up to 24 months

  3. Hip pain, function and quality of life on EQ-5D-5L Score

    hip pain, function and quality of life evaluated by the validated patient reported outcome measures EQ-5D-5L Scores preoperatively and at 2 and 6 weeks, and at 3, 6, 12, 24 months postoperatively

    Time frame: Up to 24 months

  4. PainDETECT

    PainDETECT questionnaire for identifying neuropathic pain component and patient satisfaction on a two-level scale at 6, 12, 24 months

    Time frame: Up to 24 months

  5. Nausea

    Post-operative nausea documented during the 3 first post-operative days (both incidence and intensity on a 0-10 NRS)

    Time frame: 3 days after surgery

  6. Opioids and analgesic

    Post-operative opioids and analgesic drugs consumption documented with Medication Quantification Scale score (MQS) daily during the first 6 weeks and then at 3, 6, 12, 24 months postoperatively

    Time frame: Up to 24 months

  7. PCR & ESR

    Post-operative inflammatory response in terms of hematic C-Reactive Protein (CRP) and erythrocyte sedimentation rate (ESR) documented every day in the first 3 post-operative days

    Time frame: 3 days after surgery

  8. Mobilization

    Time from surgery to first mobilization

    Time frame: Up to week 2

  9. Length of hospital stay

    The length of hospital stay

    Time frame: Up to week 2

  10. Patient Satisfaction

    the satisfaction of the patient with the surgical procedure

    Time frame: reported on a 0-10 NRS at 2 and 6 weeks, 3, 6, 12, 24 months

  11. Hip ROM

    range of movement of the operated hip

    Time frame: evaluation of range of motion preoperatively, at discharge and at 2 and 6 weeks, and at 3, 6, 12, 24 months postoperatively.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Nov 2027, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2021
First posted
Aug 26, 2021
StartActual
Dec 10, 2021
Primary completionEst.
Nov 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05023369
Lead sponsor
Ente Ospedaliero Cantonale, Bellinzona
Responsible party
Christian Candrian (Principal Investigator, Ente Ospedaliero Cantonale, Bellinzona) — Principal investigator
First posted
Aug 26, 2021
Start date
Dec 10, 2021
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Christian MD Candrian, Prof.
Contact
Gabriela.Induni-Lang@eoc.ch
0041918117029
Gabriela Induni-Lang
Contact
Gabriela.Induni-Lang@eoc.ch
0041918117029
Christian MD Candrian, Prof.
principal investigator · EOC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion